Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

NCT05559905 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

DRUG: Molnupiravir
DRUG: Placebo
BIOLOGICAL: RSV A Memphis 37b

Sponsor

Merck Sharp & Dohme LLC